Epithalon
The Russian tetrapeptide studied for telomerase activation
What Epithalon is, how it switches telomerase back on in cell culture, the course-based dosing pattern, what the research really shows versus the marketing, and its 2026 legal status.
The mechanism
It targets the enzyme that maintains the caps on your chromosomes.
A pineal-peptide analog
A four-amino-acid synthetic version of epithalamin, a pineal-gland extract from a long Russian program on peptide bioregulators and aging.
Switches on telomerase
In cultured human cells it induced the telomerase catalytic subunit (hTERT) and restored telomerase activity in cells that had none.
Telomeres lengthened
In that cell-culture system the telomere caps measurably elongated. Whether this happens in living human tissue is not confirmed.
What is shown vs what is claimed
Epithalon has a real, narrow research record. Its marketing usually describes a much bigger one.
Narrow but real
Telomerase activation in cell culture, plus lifespan and aging-biomarker effects in rodents and limited human work, almost all from one Russian research tradition.
Status: plausible, not independently confirmed
Sweeping but unproven
Phrases like reverses aging or adds years go well beyond what has been rigorously shown, and the studies behind them have not been replicated at scale by outside groups.
Status: treat specific numbers with skepticism
The honest breakdown: Epithalon human research.
What the research shows
Strongest in the lab dish, thinner as you move toward humans.
In telomerase-negative human cells, Epithalon induced hTERT and produced measurable telomere elongation. The foundational lab result.
Khavinson et al., Bull Exp Biol Med 2003 (PMID 12937682)
In female SHR mice, Epithalon affected biomarkers of aging and lifespan without increasing spontaneous tumor incidence. Rodent data, one research group.
Anisimov et al., Biogerontology 2003 (PMID 14501183)
Long-running Russian work on pineal peptides in elderly subjects reported effects on aging markers. Narrow, from the original program, not replicated at scale.
Korkushko et al., Bull Exp Biol Med 2011 (PMID 22451889)
More on the category: epigenetics and peptides.
How it is dosed
Not a daily supplement, but short courses a couple of times a year, the geroprotector pattern from Khavinson's program.
By subcutaneous injection, for 10 to 20 consecutive days. A convention from the research program, not a validated dosing trial.
The short-course, intermittent structure, rather than continuous daily use.
Educational information, not medical advice; dosing should come from a prescriber. Check your math with the dosage calculator.
Side effects
Reported as well tolerated in the limited studies, with real gaps in long-term data.
- Injection site: pain or redness where it is injected is the main practical effect.
- Telomerase and cancer: a theoretical concern, since telomerase is active in many cancers. The limited rodent data did not show more tumors, but human data is thin.
- Unknown: long-term human safety of repeated courses is not well characterized.
- Source quality: research-grade material is not tested for identity, purity or sterility.
Caution: most data comes from one research program. Anyone with a cancer history especially should treat the telomerase mechanism as an open question and talk to a doctor first.

Epithalon's legal status in 2026
Prescription compounding
Under the October 2026 draft HHS policy, licensed 503A pharmacies can compound Epitalon by injection in intermittent courses, by prescription, single-ingredient and fully tested.
Not FDA-approved
The FDA panel voted in favor on July 24, 2026, but FDA staff opposed it and it is not on the 503A list yet. The policy is a draft and nonbinding.
Research versions
Epithalon sold as a research chemical is for laboratory use only, not for human consumption, and is not covered by the HHS policy.
Updates: FDA peptide status tracker · how to get peptides legally.
What to monitor
There is no validated blood marker that tracks what Epithalon is claimed to do, so be honest about what a log can and cannot show.
- Each course, with dates and doses, since use is intermittent
- A general health panel at baseline, not as proof of an anti-aging effect
- Sleep, energy and wellbeing, scored consistently
Commercial telomere-length tests are not a validated way to judge this. The dashboard logs courses and ratings over time.

Frequently asked questions
What is Epithalon?
Epithalon, also spelled Epitalon, is a synthetic tetrapeptide with the sequence Ala-Glu-Asp-Gly (AEDG), developed in Dr. Vladimir Khavinson's laboratory at the St. Petersburg Institute of Bioregulation and Gerontology. It is a simplified synthetic version of epithalamin, a pineal-gland extract studied by the same group, and it is studied mainly for telomerase activation and biomarkers of aging.
How does Epithalon work?
Its headline mechanism is telomerase activation. Telomerase rebuilds the protective telomere caps on the ends of chromosomes, which shorten with each cell division. In laboratory experiments, Epithalon induced expression of the telomerase catalytic subunit (hTERT) and restored telomerase activity in cultured human cells, producing measurable telomere elongation in that cell-culture system. Whether that translates into meaningful telomere extension in living human tissue has not been directly confirmed.
Does Epithalon actually reverse aging or extend lifespan?
That is where marketing runs ahead of the evidence. The lab data is real but narrow: telomerase activation in cell culture, and lifespan and aging-biomarker effects in rodents, mostly from a single Russian research tradition. The human work comes largely from that same program and has not been independently replicated at scale. Treat specific claims like reverses aging or adds X years with real skepticism unless they link to something you can read and evaluate.
Is Epithalon FDA-approved or legal?
Epithalon is not FDA-approved. On July 24, 2026 the FDA's advisory committee voted in favor of adding Epitalon to the 503A compounding list, and in October 2026 HHS announced a draft enforcement-discretion policy that lets licensed 503A pharmacies compound it by prescription, by injection in intermittent courses, under strict testing and labeling rules. That is not FDA approval, it is a draft and nonbinding, and it does not cover research-chemical sellers.
What is the typical Epithalon dose?
There is no FDA-reviewed or clinically validated human dose. Protocols associated with Khavinson's research program and repeated across the research community commonly cite about 5 to 10mg per day by subcutaneous injection, in short courses of 10 to 20 consecutive days, one or two courses per year. That course-based, geroprotector pattern is a convention, not a validated dosing trial, and any medical use should come from a prescriber.
Is Epithalon the same as epithalamin?
They are related but not identical. Epithalamin is a natural peptide-rich extract of the pineal gland. Epithalon is a defined synthetic tetrapeptide designed as a simplified analog of it. Much of the older Russian human research was done on epithalamin, and Epithalon is the synthetic successor studied by the same group.
Does telomerase activation raise cancer risk?
It is a fair theoretical concern, since reactivated telomerase is a feature of many cancer cells. That said, the limited rodent work from the original research program did not report increased tumor incidence, and in some models reported the opposite. Long-term human safety is simply not well characterized, so this is an open question rather than a settled reassurance.
Track your protocol
Log each course, bloodwork and how you feel in one place, with honest expectations. Free.
Sources
- Khavinson VK, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med. 2003;135(6):590-592. PMID 12937682
- Anisimov VN, Khavinson VK, et al. Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice. Biogerontology. 2003;4(4):193-202. PMID 14501183
- Korkushko OV, Khavinson VK, Shatilo VB, Antonyuk-Shcheglova IA. Peptide geroprotector from the pituitary gland inhibits rapid aging of elderly people: results of 15-year follow-up. Bull Exp Biol Med. 2011;151(3):366-369. PMID 22451889
- FDA Pharmacy Compounding Advisory Committee vote, July 24, 2026, and the October 2026 HHS draft 503A peptide compounding policy (Epitalon acetate, injection, intermittent courses). AJMC summary
This content is for informational purposes only and is not medical advice. Epithalon is not FDA-approved in the United States. A July 2026 FDA advisory vote in its favor is nonbinding, and the October 2026 HHS compounding policy is a draft. Marketing claims of reversed aging or extended lifespan are not supported by independently replicated human trials. Research-grade Epithalon is sold for laboratory use only, not for human consumption. Always consult a qualified healthcare provider before considering any peptide protocol.